DV1
DV1 is a CXCR4 inhibitor with anti-proteolytic properties that specifically blocks the binding of SDF-1α to its receptor. DV1 inhibits the migration of breast cancer cells and enables the targeted delivery of avidin-PLGA nanoparticles to CXCR4-expressing cancer cells. DV1 not only effectively suppresses the progression of metastatic breast cancer in mouse models, but also preferentially accumulates in brain tumor tissues rather than normal brain tissues, showing potential for inhibiting intracranial tumor metastasis. As a humoral immune stimulant, DV1 induces the production of specific IgG, neutralizing antibodies and cellular immune responses, thereby providing the host with protection against lethal challenges. DV1 has been applied to studies on CXCR4-expressing cancers, glioblastoma, dengue fever and other related diseases.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C108H170N34O26S2
- 分子量:2424.85
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
SDF-1α-CXCR4 |
DV1 (100 nM; 30 min pre-incubation + 24 h) significantly inhibits SDF-1α-induced migration of human breast cancer MDA-MB-231 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 human breast cancer cells
-
Concentration:100 nM (pre-incubation); 100 nM (transwell culture)
-
Incubation Time:30 min (pre-incubation); 24 h (transwell culture)
-
Result:Significantly inhibited the migration of MDA-MB-231 cells toward the SDF-1α gradient (p < 0.01).
Left over 99% of migrated cells alive after 24 h of treatment.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NCRNU (female, 8 weeks old, intracranial metastatic breast cancer model via right hemisphere intracranial injection of 3×105 luciferase-expressing MDA-MB-231 cells)[2]
-
Dosage:50 μg/kg/day
-
Administration:intracerebroventricular; continuous infusion; starting on tumor cell injection day
-
Result:Detected roughly twice as many particles in tumor tissue compared to adjacent normal brain tissue, with statistically significant difference.
Reduced tumor incidence to 54.5% (n=22), with statistically significant difference from control's 83% (P=0.0361).
Resulted in smaller average tumor size in mice with tumors, though difference was not statistically significant.
化学情報
-
分子量 2424.85
-
分子式 C108H170N34O26S2
-
配列
d-(Leu-Gly-Ala-Ser-Trp-His-Arg-Pro-Asp-Lys-Cys-Cys-Leu-Gly-Tyr-Gln-Lys-Arg-Pro-Leu-Pro)-NH2
-
シーケンスの短縮
d-(LGASWHRPDKCCLGYQKRPLP)-NH2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Ansari S, et al. Targeting CXCR4-expressing Cancer Cells with Avidin-poly (lactic-co-glycolic acid) Nanoparticle Surface Modified with Biotinylated DV1 Peptide. Int J Appl Basic Med Res. 2023;13(2):106-112. [Content Brief]
[2]. Krishnamurthy S, et al. Hyperosmotic intraventricular drug delivery of DV1 in the management of intracranial metastatic breast cancer in a mouse model. J Clin Neurosci. 2019;62:207-211. [Content Brief]
[3]. Zheng X, et al. Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice. Front Cell Infect Microbiol. 2017;7:175. Published 2017 May 12. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
DV1 関連分類
HY-P10427 関連分類
Powered by Bioz